Program Description
Managing chronic inflammatory skin conditions such as atopic dermatitis, plaque psoriasis, and seborrheic dermatitis requires health care professionals to balance controlling flare-ups with minimizing the quality-of-life disruptions they cause patients. The complex, overlapping presentation of these conditions and the distinct safety profiles for pediatric and adult patients present challenges in treatment and management. Treatment may also be affected by attitudes toward steroids from patients and caregivers, leading to poor adherence, disease progression, and recurring symptoms that complicate long-term management. This program offers managed care professionals and pharmacists a deep dive into these overlapping dermatologic conditions across adult and pediatric patients. The discussion will examine how delayed or inadequate treatment can impact health care resource utilization and the potential for unnecessary escalation of therapy. The current therapeutic guidelines will be reviewed, as will the traditional role of topical corticosteroids and the emerging clinical data surrounding nonsteroidal topical alternatives. The session specifically addresses the practical hurdles for managed care professionals within formulary management, illustrating the effects of potentially restrictive step therapy and prior authorization protocols for patients with dermatitis.
Target audience: Managed care professionals and pharmacists
Type of activity: Application
Release date: October 21, 2026
Expiration date: October 21, 2027
Learner level: Foundational
Time to complete activity: 1.0 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Explain how undertreatment or delayed treatment in dermatitis subtypes can contribute to persistent symptoms, reduced adherence, impaired quality of life, and unnecessary escalation of therapy
- Determine the role of branded nonsteroidal topical agents as evidence-based options before escalation to biologic therapy
- Identify managed care barriers to appropriate access for branded nonsteroidal topical agents
Aderonke Adeboye, PharmD, BCPS
Clinical Pharmacy Specialist, Dermatology
Emory University Hospital Midtown
Atlanta, GA
Zachary Contreras, PharmD
Director, Pharmacy Benefits
Sharp Health Plan
San Diego, CA
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-26-330-H01-P. The activity is available for CE credit through October 21, 2027.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Faculty
Zachary Contreras, PharmD, has the following relevant financial relationships with ineligible companies to disclose:
Consultant: Ferring Pharmaceuticals, Pfizer
The following contributors have no relevant financial relationships with ineligible companies to disclose:
Aderonke Adeboye, PharmD, BCPS
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Jason Christidis, PharmD; Emily Tyler; Brianna Winters
Any relevant financial relationships listed for these individuals have been mitigated.
At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.
Educational Disclaimer
Continuing professional education activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved by the labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms
